Resectable Hepatocellular Carcinoma research hub

Perioperative Therapy with Durvalumab Plus Tremelimumab for Patients with Resectable Hepatocellular Carcinoma (HCC) - A Phase II Trial (NEOTOMA)

This study is testing two medicines, durvalumab and tremelimumab, before surgery for liver cancer. We want to see if these medicines cause side effects that stop surgery or are hard to manage. It's a Phase II trial, meaning we're looking at safety and early signs of how well it works.